ALISO VIEJO, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass Pharma”), a late-stage biopharmaceutical company, today announced that members of the executive management team will host 1x1 meetings at the Jefferies Biotech on the Bay Summit in Miami Beach, Florida on Wednesday, March 11, 2026. About SpyGlass Pharma SpyGlass Pharma is a late-stage biopharmaceutical company dedicated to transforming the treatment paradigm for patients living with chronic eye conditions ...

ALISO VIEJO, Calif., Feb. 09, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass Pharma”), a late-stage biopharmaceutical company, today announced the closing of its initial public offering of 10,781,250 shares of its common stock, which includes the exercise in full of the underwriters’ option to purchase 1,406,250 additional shares of its common stock, at a public offering price of $16.00 per share. The aggregate gross proceeds from the offering were $172.5 million, before deducting u ...

Company Overview - SpyGlass Pharma, Inc. is a late-stage biopharmaceutical company focused on transforming treatment for patients with chronic eye conditions through long-acting, sustained drug delivery of approved medicines [5] - The company was founded in 2019 by Malik Y. Kahook, M.D. and Glenn Sussman to address the lack of ophthalmic innovations that utilize durable treatment options [7] Initial Public Offering (IPO) Details - SpyGlass Pharma announced the pricing of its initial public offering of 9,375,000 shares at a public offering price of $16.00 per share, aiming for aggregate gross proceeds of approximately $150 million [1] - The underwriters have a 30-day option to purchase up to an additional 1,406,250 shares at the initial public offering price [1] - The common stock is expected to begin trading on the Nasdaq Global Select Market under the ticker symbol "SGP" on February 6, 2026, with the offering expected to close on February 9, 2026 [1] Underwriters and Regulatory Information - Jefferies, Leerink Partners, Citigroup, and Stifel are acting as joint book-running managers for the offering [2] - A registration statement for the offering was filed with the Securities and Exchange Commission and became effective on January 30, 2026 [3]